Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.(I).2 - JUNIPER PHARMACEUTICALS INC | jnp-ex312_200.htm |
| EX-32.2 - EX-32.2 - JUNIPER PHARMACEUTICALS INC | jnp-ex322_14.htm |
| EX-32.1 - EX-32.1 - JUNIPER PHARMACEUTICALS INC | jnp-ex321_10.htm |
| EX-31.1 - EX-31.(I).1 - JUNIPER PHARMACEUTICALS INC | jnp-ex311_201.htm |
| EX-23.1 - EX-23.1 - JUNIPER PHARMACEUTICALS INC | jnp-ex231_287.htm |
| EX-21 - EX-21 - JUNIPER PHARMACEUTICALS INC | jnp-ex21_264.htm |
| 10-K - 10-K - JUNIPER PHARMACEUTICALS INC | jnp-10k_20171231.htm |
Consent of Independent Registered Public Accounting Firm
Juniper Pharmaceuticals, Inc.
Boston, Massachusetts
We hereby consent to the incorporation by reference in the Registration Statements on Form S3 (Nos. 333-206928, 333-169599, 333-75275, 333-125671, 333-132803, 333-140107, 333-37976, 333-155530 and 333-38230) and Form S-8 (Nos. 333-152008, 333-188647, 333-205723, 333-116072, 333-63470, 333-34079 and 333-213433) of Juniper Pharmaceuticals, Inc. of our report dated March 10, 2016 (except for Restatement of Consolidated Financial Statements described in Note 2 and the associated effects in Note 14 in previously filed restated financial statements on Form 10-K/A, which are not presented herein and is as of November 14, 2016), relating to the consolidated statement of operations, comprehensive (loss) income, stockholders’ equity and cash flows for the year ended December 31, 2015 which appears in this Form 10-K.
/s/ BDO USA, LLP
Boston, Massachusetts
March 9, 2018